[go: up one dir, main page]

SG11201500425PA - Extended-release levetiracetam and method of preparation - Google Patents

Extended-release levetiracetam and method of preparation

Info

Publication number
SG11201500425PA
SG11201500425PA SG11201500425PA SG11201500425PA SG11201500425PA SG 11201500425P A SG11201500425P A SG 11201500425PA SG 11201500425P A SG11201500425P A SG 11201500425PA SG 11201500425P A SG11201500425P A SG 11201500425PA SG 11201500425P A SG11201500425P A SG 11201500425PA
Authority
SG
Singapore
Prior art keywords
extended
preparation
release levetiracetam
levetiracetam
release
Prior art date
Application number
SG11201500425PA
Inventor
I-Lan Tung Sue
Jung-Chung Lee
Original Assignee
Pharmtak Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmtak Inc filed Critical Pharmtak Inc
Publication of SG11201500425PA publication Critical patent/SG11201500425PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201500425PA 2012-08-08 2013-07-31 Extended-release levetiracetam and method of preparation SG11201500425PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261680789P 2012-08-08 2012-08-08
PCT/US2013/053097 WO2014025593A1 (en) 2012-08-08 2013-07-31 Extended-release levetiracetam and method of preparation

Publications (1)

Publication Number Publication Date
SG11201500425PA true SG11201500425PA (en) 2015-04-29

Family

ID=50066329

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201500425PA SG11201500425PA (en) 2012-08-08 2013-07-31 Extended-release levetiracetam and method of preparation

Country Status (9)

Country Link
US (1) US20140044780A1 (en)
EP (1) EP2882292A4 (en)
CN (1) CN104619175A (en)
AU (1) AU2013299938A1 (en)
CA (1) CA2877134A1 (en)
HK (1) HK1208130A1 (en)
SG (1) SG11201500425PA (en)
TW (1) TW201410267A (en)
WO (1) WO2014025593A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105142623A (en) 2013-03-15 2015-12-09 艾吉因生物股份有限公司 Methods and compositions for improving cognitive function
GB201411196D0 (en) * 2014-06-24 2014-08-06 Dupont Nutrition Biosci Aps Composition and use thereof
US10159648B2 (en) * 2015-05-22 2018-12-25 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
CN107167401B (en) * 2017-05-18 2020-01-07 湖南洞庭药业股份有限公司 Levetiracetam sustained-release tablet pharmaceutical composition and quality control and preparation method thereof
JP7264711B2 (en) * 2019-04-26 2023-04-25 東和薬品株式会社 Method for producing pharmaceutical composition containing levetiracetam
MX2024001034A (en) 2021-07-23 2024-02-23 Neuraxpharm Pharmaceuticals S L Multiparticulate pharmaceutical composition.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050250838A1 (en) * 2004-05-04 2005-11-10 Challapalli Prasad V Formulation for sustained delivery
EA014249B1 (en) * 2005-01-27 2010-10-29 Алембик Лимитед Formulation of extended release levetiracetam
US8431156B2 (en) * 2005-02-22 2013-04-30 Sun Pharma Advanced Research Company Ltd. Pharmaceutical composition
WO2008062446A2 (en) * 2006-09-14 2008-05-29 Alembic Limited An extended release composition of levetiracetam, which exhibits no adverse food effect
US20120003307A1 (en) * 2007-11-29 2012-01-05 Ranbaxy Laboratories Limited Levetiracetam controlled release composition
US20100323016A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
WO2010026467A2 (en) * 2008-09-04 2010-03-11 Torrent Pharmaceuticals Ltd. Controlled release dosage form of high solubility active ingredient
CN101647789B (en) * 2009-09-01 2011-08-17 天津药物研究院药业有限责任公司 Levetiracetam sustained-release pellet capsule preparation

Also Published As

Publication number Publication date
EP2882292A4 (en) 2016-04-06
HK1208130A1 (en) 2016-02-26
CA2877134A1 (en) 2014-02-13
US20140044780A1 (en) 2014-02-13
TW201410267A (en) 2014-03-16
WO2014025593A1 (en) 2014-02-13
AU2013299938A1 (en) 2015-01-22
EP2882292A1 (en) 2015-06-17
CN104619175A (en) 2015-05-13

Similar Documents

Publication Publication Date Title
IL263020A (en) Novel modulators and methods of use
IL262110A (en) Dll3 modulators and methods of use
ZA201501858B (en) Anti-mcam antibodies and associated methods of use
ZA201502503B (en) Hppd variants and methods of use
ZA201405540B (en) Packaging and method of packaging
SG11201504049VA (en) Compounds and their methods of use
IL227333A0 (en) Methods for prepar5iaon of glycosphingolipids and uses thereof
ZA201404675B (en) Anti-lrp5 antibodies and methods of use
GB201218831D0 (en) Permenter and the method of fermentation
IL233481A0 (en) Peptides and methods of using same
HRP20181704T1 (en) Crystal form of chidamide, preparation method and use thereof
SG11201408326TA (en) Preparation method for perfluoro-2-methyl-3-pentanone and intermediate
SG11201500425PA (en) Extended-release levetiracetam and method of preparation
SG11201500474PA (en) Nutriculture member and nutriculture method
ZA201408128B (en) Etract of greyia radlkoferi and use thereof
GB2493595B (en) Wheelchair and method of construction
GB201217309D0 (en) Packaging and method of making packaging
GB201210911D0 (en) Clamping means and method of use thereof